Day One Biopharmaceuticals (DAWN) Competitors $6.75 -0.23 (-3.30%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$6.86 +0.11 (+1.56%) As of 06/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. MOR, IMVT, HCM, IBRX, AAPG, OGN, APLS, XENE, AMRX, and MIRMShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include MorphoSys (MOR), Immunovant (IMVT), HUTCHMED (HCM), ImmunityBio (IBRX), Ascentage Pharma Group International (AAPG), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors MorphoSys Immunovant HUTCHMED ImmunityBio Ascentage Pharma Group International Organon & Co. Apellis Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Day One Biopharmaceuticals (NASDAQ:DAWN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations. Do insiders & institutionals believe in DAWN or MOR? 87.9% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, DAWN or MOR? Day One Biopharmaceuticals has a beta of -1.3, meaning that its share price is 230% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Which has better earnings and valuation, DAWN or MOR? Day One Biopharmaceuticals has higher earnings, but lower revenue than MorphoSys. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$161.92M4.23-$188.92M-$0.71-9.51MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media prefer DAWN or MOR? In the previous week, Day One Biopharmaceuticals had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Day One Biopharmaceuticals and 0 mentions for MorphoSys. Day One Biopharmaceuticals' average media sentiment score of 0.38 beat MorphoSys' score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Day One Biopharmaceuticals Neutral MorphoSys Neutral Does the MarketBeat Community believe in DAWN or MOR? Day One Biopharmaceuticals received 31 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 70.89% of users gave Day One Biopharmaceuticals an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes5670.89% Underperform Votes2329.11% MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Is DAWN or MOR more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Day One Biopharmaceuticals' return on equity of -22.40% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% MorphoSys -226.79%-694.31%-22.55% Do analysts rate DAWN or MOR? Day One Biopharmaceuticals currently has a consensus target price of $30.57, suggesting a potential upside of 352.91%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Day One Biopharmaceuticals is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryDay One Biopharmaceuticals beats MorphoSys on 15 of the 19 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$684.19M$6.85B$5.57B$8.61BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-6.558.7827.1720.06Price / Sales4.23255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book1.706.557.064.70Net Income-$188.92M$143.93M$3.23B$247.88M7 Day Performance-2.88%3.97%2.89%2.66%1 Month Performance2.58%11.32%9.06%6.40%1 Year Performance-48.08%4.20%31.40%14.07% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals1.7205 of 5 stars$6.75-3.3%$30.57+352.9%-46.2%$684.19M$161.92M-6.5560MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant1.4501 of 5 stars$16.29-2.9%$38.33+135.3%-35.7%$2.78BN/A-6.22120Positive NewsAnalyst RevisionHCMHUTCHMED1.3586 of 5 stars$15.96+4.0%$19.00+19.0%-4.2%$2.78B$630.20M0.001,760Positive NewsUpcoming EarningsHigh Trading VolumeIBRXImmunityBio2.3442 of 5 stars$3.44+9.2%$12.25+256.1%-45.6%$2.78B$31.22M-3.74590High Trading VolumeAAPGAscentage Pharma Group InternationalN/A$29.88+5.3%N/AN/A$2.60B$980.65M0.00600OGNOrganon & Co.4.7934 of 5 stars$9.76+2.1%$18.00+84.4%-50.1%$2.54B$6.29B2.9310,000Trending NewsAPLSApellis Pharmaceuticals4.7118 of 5 stars$19.39+0.6%$40.05+106.6%-54.9%$2.44B$775.84M-9.55770Analyst RevisionXENEXenon Pharmaceuticals3.5091 of 5 stars$31.45-0.6%$54.82+74.3%-15.0%$2.41B$7.50M-11.15210Positive NewsAnalyst RevisionAMRXAmneal Pharmaceuticals3.7149 of 5 stars$7.61-0.1%$11.60+52.4%+10.7%$2.39B$2.83B-11.197,600Positive NewsMIRMMirum Pharmaceuticals3.8483 of 5 stars$47.05+1.4%$60.73+29.1%+85.0%$2.33B$379.25M-23.29140Analyst Revision Related Companies and Tools Related Companies MorphoSys Competitors Immunovant Competitors HUTCHMED Competitors ImmunityBio Competitors Ascentage Pharma Group International Competitors Organon & Co. Competitors Apellis Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DAWN Stock Free DAWN Stock Alerts